Tridek-One’s website
Paris, FR · Founded 2018 · 14 employees on LinkedIn · 5 known investors
Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases. Its lead program is a CD31×GPVI bispecific antibody for thromboinflammatory cardiovascular diseases, aiming to provide antithrombotic and anti-inflammatory effects while minimizing bleeding risk.
Investors · 5
Frequently asked questions
- What does Tridek-One’s website do?
- Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases. Its lead program is a CD31×GPVI bispecific antibody for thromboinflammatory cardiovascular diseases, aiming to provide antithrombotic and anti-inflammatory effects while minimizing bleeding risk.
- Who are Tridek-One’s website's investors?
- Tridek-One’s website's investors include Advent Life Sciences, Bioqube Ventures, Bpifrance, Pureos Bioventures, AdBio partners.
- Where is Tridek-One’s website headquartered?
- Tridek-One’s website is headquartered in Paris, FR.